Recommendations regarding the clinical protocols for radionuclides of choice and diagnostic criteria for renovascular hypertension have been established by the consensus report on captopril renography. A review of the existing data indicates that postcaptopril renography alone is a safe and effective means of noninvasively screening hypertensive patients. A normal radionuclide study after captopril suggests with a reasonable degree of certainty that potentially reversible renovascular hypertension is unlikely. A positive study in an appropriately screened hypertensive patient with preserved renal function suggests renovascular disease is likely with a sensitivity and specificity in excess of 90%. In the comparative studies of Elliott and Miralles and colleagues, captopril renography was a more sensitive and specific screening test than the captopril plasma renin activity test. Although there may be confounding variables, such as renal dysfunction, medications, and types of stenosis, a positive captopril renogram may suggest a cure or improvement in blood pressure control with successful intervention such as PTRA or revascularization. Whether captopril renography can predict stabilization of individual kidney function is speculative and deserving of further study.